Publication

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF

Suzuki, T., Yazaki, Y., Voors, A. A., Jones, D. J. L., Chan, D. C. S., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., Hillege, H. L., Lang, C. C., Ponikowski, P., Samani, N. J., van Veldhuisen, D. J., Zannad, F., Zwinderman, A. H., Metra, M. & Ng, L. L., Jul-2019, In : European Journal of Heart Failure. 21, 7, p. 877-886 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Suzuki, T., Yazaki, Y., Voors, A. A., Jones, D. J. L., Chan, D. C. S., Anker, S. D., ... Ng, L. L. (2019). Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. European Journal of Heart Failure, 21(7), 877-886. https://doi.org/10.1002/ejhf.1338

Author

Suzuki, Toru ; Yazaki, Yoshiyuki ; Voors, Adriaan A. ; Jones, Donald J. L. ; Chan, Daniel C. S. ; Anker, Stefan D. ; Cleland, John G. ; Dickstein, Kenneth ; Filippatos, Gerasimos ; Hillege, Hans L. ; Lang, Chim C. ; Ponikowski, Piotr ; Samani, Nilesh J. ; van Veldhuisen, Dirk J. ; Zannad, Faiez ; Zwinderman, Aeilko H. ; Metra, Marco ; Ng, Leong L. / Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure : results from BIOSTAT-CHF. In: European Journal of Heart Failure. 2019 ; Vol. 21, No. 7. pp. 877-886.

Harvard

Suzuki, T, Yazaki, Y, Voors, AA, Jones, DJL, Chan, DCS, Anker, SD, Cleland, JG, Dickstein, K, Filippatos, G, Hillege, HL, Lang, CC, Ponikowski, P, Samani, NJ, van Veldhuisen, DJ, Zannad, F, Zwinderman, AH, Metra, M & Ng, LL 2019, 'Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF', European Journal of Heart Failure, vol. 21, no. 7, pp. 877-886. https://doi.org/10.1002/ejhf.1338

Standard

Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure : results from BIOSTAT-CHF. / Suzuki, Toru; Yazaki, Yoshiyuki; Voors, Adriaan A.; Jones, Donald J. L.; Chan, Daniel C. S.; Anker, Stefan D.; Cleland, John G.; Dickstein, Kenneth; Filippatos, Gerasimos; Hillege, Hans L.; Lang, Chim C.; Ponikowski, Piotr; Samani, Nilesh J.; van Veldhuisen, Dirk J.; Zannad, Faiez; Zwinderman, Aeilko H.; Metra, Marco; Ng, Leong L.

In: European Journal of Heart Failure, Vol. 21, No. 7, 07.2019, p. 877-886.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD et al. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. European Journal of Heart Failure. 2019 Jul;21(7):877-886. https://doi.org/10.1002/ejhf.1338


BibTeX

@article{e4afdd84bd704f349138aafdf444ea72,
title = "Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF",
abstract = "Aims Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse outcomes in patients with heart failure (HF) has been described. However, response of TMAO levels to treatment and medications has not been investigated. Therefore, we investigated whether TMAO levels are responsive to guideline-recommended treatment and medications, and further reflect changes in outcomes.Methods and results TMAO levels were investigated in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to guideline-recommended pharmacological treatment. TMAO levels in 2234 patients with new-onset or progressively worsening HF showed strong associations with adverse events (mortality and/or rehospitalisation) at 1, 2 and 3 years [hazard ratio (HR) 1.37-1.51, PConclusion TMAO levels were associated with adverse outcomes (mortality and/or rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmacological treatment in contrast to BNP levels which did as expected. Lower TMAO levels were associated with favourable outcome regardless of treatment.",
keywords = "Heart failure, Gut microbiome, Biomarker, Metabolite, Outcome study, NATRIURETIC PEPTIDE, PROGNOSTIC VALUE, MORTALITY, HOSPITALIZATION, SURVIVAL",
author = "Toru Suzuki and Yoshiyuki Yazaki and Voors, {Adriaan A.} and Jones, {Donald J. L.} and Chan, {Daniel C. S.} and Anker, {Stefan D.} and Cleland, {John G.} and Kenneth Dickstein and Gerasimos Filippatos and Hillege, {Hans L.} and Lang, {Chim C.} and Piotr Ponikowski and Samani, {Nilesh J.} and {van Veldhuisen}, {Dirk J.} and Faiez Zannad and Zwinderman, {Aeilko H.} and Marco Metra and Ng, {Leong L.}",
year = "2019",
month = "7",
doi = "10.1002/ejhf.1338",
language = "English",
volume = "21",
pages = "877--886",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Wiley",
number = "7",

}

RIS

TY - JOUR

T1 - Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure

T2 - results from BIOSTAT-CHF

AU - Suzuki, Toru

AU - Yazaki, Yoshiyuki

AU - Voors, Adriaan A.

AU - Jones, Donald J. L.

AU - Chan, Daniel C. S.

AU - Anker, Stefan D.

AU - Cleland, John G.

AU - Dickstein, Kenneth

AU - Filippatos, Gerasimos

AU - Hillege, Hans L.

AU - Lang, Chim C.

AU - Ponikowski, Piotr

AU - Samani, Nilesh J.

AU - van Veldhuisen, Dirk J.

AU - Zannad, Faiez

AU - Zwinderman, Aeilko H.

AU - Metra, Marco

AU - Ng, Leong L.

PY - 2019/7

Y1 - 2019/7

N2 - Aims Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse outcomes in patients with heart failure (HF) has been described. However, response of TMAO levels to treatment and medications has not been investigated. Therefore, we investigated whether TMAO levels are responsive to guideline-recommended treatment and medications, and further reflect changes in outcomes.Methods and results TMAO levels were investigated in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to guideline-recommended pharmacological treatment. TMAO levels in 2234 patients with new-onset or progressively worsening HF showed strong associations with adverse events (mortality and/or rehospitalisation) at 1, 2 and 3 years [hazard ratio (HR) 1.37-1.51, PConclusion TMAO levels were associated with adverse outcomes (mortality and/or rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmacological treatment in contrast to BNP levels which did as expected. Lower TMAO levels were associated with favourable outcome regardless of treatment.

AB - Aims Association of elevated circulating levels of trimethylamine N-oxide (TMAO) with adverse outcomes in patients with heart failure (HF) has been described. However, response of TMAO levels to treatment and medications has not been investigated. Therefore, we investigated whether TMAO levels are responsive to guideline-recommended treatment and medications, and further reflect changes in outcomes.Methods and results TMAO levels were investigated in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), which addressed response to guideline-recommended pharmacological treatment. TMAO levels in 2234 patients with new-onset or progressively worsening HF showed strong associations with adverse events (mortality and/or rehospitalisation) at 1, 2 and 3 years [hazard ratio (HR) 1.37-1.51, PConclusion TMAO levels were associated with adverse outcomes (mortality and/or rehospitalisation) in BIOSTAT-CHF, and did not respond to guideline-based pharmacological treatment in contrast to BNP levels which did as expected. Lower TMAO levels were associated with favourable outcome regardless of treatment.

KW - Heart failure

KW - Gut microbiome

KW - Biomarker

KW - Metabolite

KW - Outcome study

KW - NATRIURETIC PEPTIDE

KW - PROGNOSTIC VALUE

KW - MORTALITY

KW - HOSPITALIZATION

KW - SURVIVAL

U2 - 10.1002/ejhf.1338

DO - 10.1002/ejhf.1338

M3 - Article

VL - 21

SP - 877

EP - 886

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 7

ER -

ID: 93759968